AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Targeting Muco-Obstructive Lesions to Redefine COPD Treatment

3:45 pm - Tuesday 15th September 2026

Mucus plugs represent the last untargeted cause of airway obstruction in COPD, persisting even in patients escalated to triple therapy or biologics
MLT-001 by MucoLife Therapeutics is a first-in-class inhaled mucus modulator with a novel mechanism of action that directly dissolves mucus plugs with demonstrated 90% preclinical efficacy and a wide therapeutic index
The talk will highlight the addressable COPD subgroup and how MLT-001 is positioned as a once-daily inhaled add-on maintenance therapy within the existing treatment paradigm. Additionally, the presentation will explore the broader platform potential of this mechanism across other muco-obstructive diseases, including non-CF bronchiectasis, asthma

Thaher Pelaseyed

Co-founder & Chief Executive Officer

MucoLife Therapeutics